eFoodSafety.com, Inc. (OTCBB: EFSF, www.efoodsafety.com) reports successful studies illustrating Citroxin’sTM ability to eradicate the H5N1 avian influenza (bird flu) virus in a chick embryo model. Preliminary studies were conducted at Chulalongkorn University in Bangkok, Thailand, one of a few labs in Asia used by the U.S. Centers of Disease Control (CDC) to conduct research on treatments of H5N1.
The results of this study will be presented as a poster presentation at the International Influenza Conference (www.biotec.or.th/AIConf2008), to be held in Bangkok, Thailand, January 23-25, 2008. The conference will be attended by nearly six hundred participants focused on avian influenza, including representatives from eFoodSafety as well as leading scientists and businesses from sixty-five countries.
The lead investigator of the study, states, “We are highly encouraged by these results and look forward to conducting additional studies to confirm the safety and effectiveness in eradicating H5N1.”
Patricia Gruden, CEO of eFoodSafety, says, “These findings are considered to be a breakthrough in the field of treatment against bird flu, and we believe that our results mark a critical development in the global initiative to eradicate the disease. This is yet another example of how eFoodSafety is committed to improving health conditions affecting people across the world.”
Over the past few years, H5N1 has begun to spread throughout Asia and other parts of the world, with major health and economic repercussions. According to the World Health Organization (WHO), of all bird influenza types, the H5N1 virus is of greatest concern due to its ability to cause disease and death in human populations, and to develop the characteristics of a pandemic. In 2006, WHO estimated that global costs to fight avian influenza over the next two to three years will amount to between $1.2 and $1.5 billion.
About eFoodSafety.com
eFoodSafety.com, Inc., based in Scottsdale, Arizona, is dedicated to improving health conditions around the world through its innovative technologies. The company’s Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Citroxin™ (formerly named Big Six Plus) – EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The OraPhyte™ product, which has been tested and shown to be effective at eradicating nematodes by the U.S. Department of Agriculture, is currently at three major universities with outstanding Agricultural Departments undergoing crop-specific research.
The company’s Cinnergen™ is a clinically-studied, non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism, is available for sale at (www.cinnergen.com) and through national retailers; its Cinnechol™ is a multi-faceted nutritional supplement specifically designed to naturally reduce total cholesterol levels without causing any side effects. The company has entered into a joint venture agreement with CK41 Direct, Inc. to launch the PurEffect™ anti-acne skin care system.
The company’s iBoost, Inc. subsidiary is the distributor of the Immune Boost Bar™, a non-dairy, no refined sugar, all-natural and comprehensive multi-nutrient product that helps fortify the body’s immune system. The product contains Citroxin™, eFoodSafety’s proprietary all natural supplement proven effective in fighting several types of harmful bacteria, and forty active compounds that assist with enhancing immunity, detoxification, cleansing, and metabolic efficiency. The Immune Boost Bar™ is available in three delicious flavors: chocolate, oatmeal-raisin, mint and peanut butter and can be purchased at www.immuneboost.com.
The company’s MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It is the owner of the Talsyn™-CI/bid Scar Cream, a product that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com), as well as seven (7) other products in the Talsyn™ line.
Please visit the company’s website at: http://www.efoodsafety.com.
Safe Harbor Forward-Looking Statements
Statements contained in this release that are not strictly historical are “forward-looking statements.” Such forward-looking statements are sometimes identified by words such as “intends,” “anticipates,” “believes,” “expects” and “hopes.” The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company’s actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company’s products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the Company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.